Fused Azole Heterocycles as AHR Antagonists

1 . A compound chosen from

and pharmaceutically acceptable salts of any of the foregoing.

2 . A compound chosen from

and pharmaceutically acceptable salts of any of the foregoing.

3 . A pharmaceutical composition comprising at least one entity chosen from compounds of claim 1 , the compounds of claim 2

compounds of formula I

compounds of formula (II)

with the proviso that the compound is not

compounds of formula (III)

compounds of formula (IV)

compounds of formula (V)

compounds of formula (VI)

compounds of formula (VII)

and pharmaceutically acceptable salts of any of the foregoing, and at least one pharmaceutically acceptable excipient.

4 . A method of treating a disease or condition associated with aberrant AhR signaling in a subject in need thereof comprising administering to the subject a pharmaceutical composition according to claim 3 or a therapeutically effective amount of at least one entity chosen from

compounds of claim 1 ,

compounds of claim 2 ,

compounds of formula I

compounds of formula (II)

with the proviso that the compound is not

compounds of formula (III)

compounds of formula (IV)

compounds of formula (V)

compounds of formula (VI)

compounds of formula (VII)

and pharmaceutically acceptable salts of any of the foregoing,

wherein

Ring A is chosen from optionally substituted aryls, optionally substituted heteroaryls, optionally substituted cycloalkyls, and optionally substituted heterocycloalkyls;

Ring B is chosen from optionally substituted aryls, optionally substituted heteroaryls, optionally substituted cycloalkyls, and optionally substituted heterocycloalkyls; and

L is chosen from a bond and —NT 1 -C(O)—, wherein T 1 is H or Me.

5 . A method of treating a disease or condition associated with aberrant AhR signaling in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition according to claim 3 or a therapeutically effective amount of at least one entity chosen from compounds of any one of claims 1 and 2 , compounds of Formula I

compounds of formula (II)

with the proviso that the compound is not

compounds of formula (III)

compounds of formula (IV)

compounds of formula (V)

compounds of formula (VI)

compounds of formula (VII)

and pharmaceutically acceptable salts thereof,

wherein

Ring A is chosen from optionally substituted aryls, optionally substituted heteroaryls, optionally substituted cycloalkyls, and optionally substituted heterocycloalkyls;

Ring B is chosen from optionally substituted aryls, optionally substituted heteroaryls, optionally substituted cycloalkyls, and optionally substituted heterocycloalkyls; and

L is chosen from a bond and —NT 1 -C(O)—, wherein T 1 is H or Me.

6 . A method of treating a disease or condition mediated by AhR signaling in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition according to claim 3 or a therapeutically effective amount of at least one entity chosen from compounds of any one of claims 1 and 2 , compounds of Formula I

compounds of formula (II)

with the proviso that the compound is not

compounds of formula (III)

compounds of formula (IV)

compounds of formula (V)

compounds of formula (VI)

compounds of formula (VII)

and pharmaceutically acceptable salts thereof,

wherein

Ring A is chosen from optionally substituted aryls, optionally substituted heteroaryls, optionally substituted cycloalkyls, and optionally substituted heterocycloalkyls;

Ring B is chosen from optionally substituted aryls, optionally substituted heteroaryls, optionally substituted cycloalkyls, and optionally substituted heterocycloalkyls; and

L is chosen from a bond and —NT 1 -C(O)—, wherein T 1 is H or Me.

7 . A method of inhibiting cancer cell proliferation mediated by AhR signaling in a subject in need thereof comprising administering to the subject a pharmaceutical composition according to claim 3 or a therapeutically effective amount of at least one entity chosen from compounds of any one of claims 1 and 2 , compounds of Formula I

compounds of formula (II)

with the proviso that the compound is not

compounds of formula (III)

compounds of formula (IV)

compounds of formula (V)

compounds of formula (VI)

compounds of formula (VII)

and pharmaceutically acceptable salts thereof,

wherein

Ring A is chosen from optionally substituted aryls, optionally substituted heteroaryls, optionally substituted cycloalkyls, and optionally substituted heterocycloalkyls;

Ring B is chosen from optionally substituted aryls, optionally substituted heteroaryls, optionally substituted cycloalkyls, and optionally substituted heterocycloalkyls; and

L is chosen from a bond and —NT 1 -C(O)—, wherein T 1 is H or Me.

8 . A method of inhibiting tumor cell invasion or metastasis mediated by AhR signaling in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition according to claim 3 or a therapeutically effective amount of at least one entity chosen from compounds of any one of claims 1 and 2 , compounds of Formula I

compounds of formula (II)

with the proviso that the compound is not

compounds of formula (III)

compounds of formula (IV)

compounds of formula (V)

compounds of formula (VI)

compounds of formula (VII)

and pharmaceutically acceptable salts thereof,

wherein

Ring A is chosen from optionally substituted aryls, optionally substituted heteroaryls, optionally substituted cycloalkyls, and optionally substituted heterocycloalkyls;

Ring B is chosen from optionally substituted aryls, optionally substituted heteroaryls, optionally substituted cycloalkyls, and optionally substituted heterocycloalkyls; and

L is chosen from a bond and —NT 1 -C(O)—, wherein T 1 is H or Me.

9 . The method according to any one of claims 4 - 8 , wherein the at least one entity is chosen from compounds of any one of claims 1 and 2 and pharmaceutically acceptable salts thereof.

10 . The method according to any one of claims 4 - 8 , wherein the least one entity is chosen from:

(i) 1-Methyl-N-(5-(2-(trifluoromethyl)phenyl)thiazolo[5,4-b]pyridin-2-yl)-1H-pyrazole-5-carboxamide;

(ii) 1-Methyl-N-(5-(2-(trifluoromethyl)phenyl)thiazolo[5,4-b]pyridin-2-yl)-1H-1,2,4-triazole-5-carboxamide;

(iii) 1-Methyl-N-(5-(o-tolyl)thiazolo[5,4-b]pyridin-2-yl)-1H-1,2,4-triazole-5-carboxamide;

(iv) N-(5-(2-(difluoromethyl)phenyl)thiazolo[5,4-b]pyridin-2-yl)-1-methyl-1H-pyrazole-5-carboxamide;

(v) N-(5-(2-(difluoromethyl)phenyl)thiazolo[5,4-b]pyridin-2-yl)-1-methyl-1H-1,2,4-triazole-5-carboxamide;

(vi) N-(5-(o-tolyl)thiazolo[5,4-b]pyridin-2-yl)picolinamide;

(vii) N-(5-(o-tolyl)thiazolo[5,4-b]pyridin-2-yl)nicotinamide;

(viii) N-(5-(o-tolyl)thiazolo[5,4-b]pyridin-2-yl)isonicotinamide;

(ix) N-(5-(2-methoxyphenyl)thiazolo[5,4-b]pyridin-2-yl)-1-methyl-1H-1,2,4-triazole-5-carboxamide;

(x) N-(5-(2-(difluoromethyl)-5-fluorophenyl)thiazolo[5,4-b]pyridin-2-yl)-1-methyl-1H-pyrazole-5-carboxamide;

(xi) N-(5-(2-(difluoromethyl)-5-fluorophenyl)thiazolo[5,4-b]pyridin-2-yl)-1-methyl-1H-1,2,4-triazole-5-carboxamide;

(xii) N-(5-(2-methoxyphenyl)thiazolo[5,4-b]pyridin-2-yl)picolinamide;

(xiii) N-(5-(2-methoxyphenyl)thiazolo[5,4-b]pyridin-2-yl)nicotinamide;

(xiv) N-(5-(2-methoxyphenyl)thiazolo[5,4-b]pyridin-2-yl)isonicotinamide;

(xv) 1-Methyl-N-(5-(o-tolyl)thiazolo[5,4-b]pyridin-2-yl)-1H-pyrazole-5-carboxamide;

(xvi) N-(5-(3-methoxyphenyl)thiazolo[5,4-b]pyridin-2-yl)-1-methyl-1H-pyrazole-5-carboxamide;

(xvii) N-(5-(3-(dimethylcarbamoyl)phenyl)thiazolo[5,4-b]pyridin-2-yl)-1-methyl-1H-pyrazole-5-carboxamide;

(xviii) N-(5-(2-(dimethylamino)phenyl)thiazolo[5,4-b]pyridin-2-yl)-1-methyl-1H-pyrazole-5-carboxamide;

(xix) N-(5-(3-(dimethylamino)phenyl)thiazolo[5,4-b]pyridin-2-yl)-1-methyl-1H-pyrazole-5-carboxamide;

(xx) N-(5-(4-(dimethylamino)phenyl)thiazolo[5,4-b]pyridin-2-yl)-1-methyl-1H-pyrazole-5-carboxamide;

(xxi) 1-Methyl-N-(5-(2-(pyrrolidin-1-yl)phenyl)thiazolo[5,4-b]pyridin-2-yl)-1H-pyrazole-5-carboxamide;

(xxii) 1-Methyl-N-(5-(1-methyl-1H-pyrazol-4-yl)thiazolo[5,4-b]pyridin-2-yl)-1H-pyrazole-5-carboxamide;

(xxiii) N-(5-(2-(dimethylamino)phenyl)thiazolo[5,4-b]pyridin-2-yl)acetamide;

(xxiv) N-(5-(2-hydroxyphenyl)thiazolo[5,4-b]pyridin-2-yl)-1-methyl-1H-pyrazole-5-carboxamide;

(xxv) N-(5-(2-methoxyphenyl)thiazolo[5,4-b]pyridin-2-yl)-1-methyl-1H-pyrazole-5-carboxamide;

(xxvi) 1-Methyl-N-(5-(pyridin-3-yl)thiazolo[5,4-b]pyridin-2-yl)-1H-pyrazole-5-carboxamide;

(xxvii) 1-Methyl-N-(5-(pyridin-2-yl)thiazolo[5,4-b]pyridin-2-yl)-1H-pyrazole-5-carboxamide;

(xxviii) 1-Methyl-N-(5-(thiazol-2-yl)thiazolo[5,4-b]pyridin-2-yl)-1H-pyrazole-5-carboxamide;

(xxix) N-(5-(4,5-dimethylthiazol-2-yl)thiazolo[5,4-b]pyridin-2-yl)-1-methyl-1H-pyrazole-5-carboxamide;

(xxx) 1-Methyl-N-(5-(5-methylthiazol-2-yl)thiazolo[5,4-b]pyridin-2-yl)-1H-pyrazole-5-carboxamide;

(xxxi) 1-Methyl-N-(5-(4-methylthiazol-5-yl)thiazolo[5,4-b]pyridin-2-yl)-1H-pyrazole-5-carboxamide;

(xxxii) 1-Methyl-N-(5-(4-methylthiazol-2-yl)thiazolo[5,4-b]pyridin-2-yl)-1H-pyrazole-5-carboxamide;

(xxxiii) N-(5-(2,4-dimethylthiazol-5-yl)thiazolo[5,4-b]pyridin-2-yl)-1-methyl-1H-pyrazole-5-carboxamide;

(xxxiv) N-(5-(2-isobutyramidophenyl)thiazolo[5,4-b]pyridin-2-yl)-1-methyl-1H-pyrazole-5-carboxamide;

(xxxv) N-(5-(2-acetamidophenyl)thiazolo[5,4-b]pyridin-2-yl)-1-methyl-1H-pyrazole-5-carboxamide;

(xxxvi) 1-Methyl-N-(5-(2-(N-methylacetamido)phenyl)thiazolo[5,4-b]pyridin-2-yl)-1H-pyrazole-5-carboxamide;

(xxxvii) N-(5-(2-((2-hydroxyethyl)(methyl)amino)phenyl)thiazolo[5,4-b]pyridin-2-yl)-1-methyl-1H-pyrazole-5-carboxamide;

(xxxviii) N-Methyl-N-(5-(o-tolyl)thiazolo[5,4-b]pyridin-2-yl)picolinamide;

(xxxix) N-(5-(o-tolyl)thiazolo [5,4-b]pyridin-2-yl)morpholine-4-carboxamide;

(xl) 4-Methyl-N-(5-(o-tolyl)thiazolo[5,4-b]pyridin-2-yl)piperazine-1-carboxamide; and

pharmaceutically acceptable salts of any of the foregoing.

11 . The method according to any one of claims 4 - 8 , wherein Ring A is chosen from optionally substituted 6-10 membered aryls, optionally substituted 5-10 membered heteroaryls, optionally substituted 3-10 membered cycloalkyls, and optionally substituted 3-10 membered heterocycloalkyls.

12 . The method according to any one of claims 4 - 11 , wherein Ring A is chosen from phenyl, pyrrolyl, furanyl, furazanyl, thiophenyl, imidazolyl, isothiazoyl, isoxazolyl, oxazolyl, oxadiazolyl, tetrazolyl, thiazolyl, triazolyl, pyrazolyl, pyridinyl, pyrazinyl, pyridazinyl, and pyrimidinyl, each of which may be substituted with one or more substituents, which may be the same or different.

13 . The method according to any one of claims 4 - 11 , wherein Ring A is chosen from

14 . The method according to any one of claims 4 - 13 , wherein Ring B is chosen from optionally substituted 6-10 membered aryls, optionally substituted 5-10 membered heteroaryls, optionally substituted 3-10 membered cycloalkyls, and optionally substituted 3-10 membered heterocycloalkyls.

15 . The method according to any one of claims 4 - 14 , wherein Ring B is chosen from phenyl, pyrrolyl, furanyl, furazanyl, thiophenyl, imidazolyl, isothiazoyl, isoxazolyl, oxazolyl, oxadiazolyl, tetrazolyl, thiazolyl, triazolyl, pyrazolyl, pyridinyl, pyrazinyl, pyridazinyl, pyridinonyl, pyrimidinyl, piperidinyl, piperazinyl, and morpholinyl each of which may be substituted with one or more substituents, which may be the same or different.

16 . The method according to any one of claims 4 - 14 , wherein Ring B is chosen from

17 . The method according to any one of claims 4 - 16 , wherein L is a bond, —NH(C═O)—, or —NCH 3 (C═O)—.

18 . The method of any one of claims 4 - 17 , wherein the disease is chosen from cancers.

19 . The method of any one of claims 4 - 18 , wherein the disease is chosen from breast cancers, respiratory tract cancers, brain cancers, cancers of reproductive organs, digestive tract cancers, urinary tract cancers, eye cancers, liver cancers, skin cancers, head and neck cancers, thyroid cancers, parathyroid cancers, and metastases of any of the foregoing.

20 . The method of any one of claims 4 - 18 , wherein the disease is chosen from lymphomas, sarcomas, melanomas, glioblastomas, and leukemias.

21 . The method of any one of claims 4 to 20 , further comprising administering to the subject a therapeutically effective amount of at least one immune checkpoint inhibitor.

22 . The method of claim 21 , wherein the immune checkpoint inhibitor is chosen from PD-1 inhibitors, PD-L1 inhibitors, and CTLA-4 blockers.